JC
Jonathan Chang Leerink Partners Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Replimune Group
REPL
$494M
| $6.33 | $3 |
53%
downside
| Market Perform |
22 Jul ‘25
1 month ago |
|
2
Zai Lab
ZLAB
$3.42B
| $30.76 | $75 |
144%
upside
| Outperform |
30 Jun ‘25
2 months ago |
|
3
Genmab
GMAB
$16.9B
| $27.54 | $27 |
2%
downside
| Outperform |
13 Feb ‘25
6 months ago |
|
4
Immunocore
IMCR
$1.87B
| $37.20 | $74 |
99%
upside
| Outperform |
29 Apr ‘24
1 year ago |
|
|
NBTX
5
Nanobiotix
NBTX
$419M
| $8.70 | $11 |
26%
upside
| Outperform |
8 Dec ‘23
1 year ago |
|
6
NovoCure
NVCR
$1.37B
| $12.28 | $51 |
315%
upside
| Outperform |
4 Aug ‘23
2 years ago |
|
7
Karyopharm Therapeutics
KPTI
$57.2M
| $6.60 | $75 |
1,036%
upside
| Market Perform |
10 Jan ‘23
2 years ago |
|
|
8
Replimune Group
REPL
$494M
| $6.33 | $34 |
437%
upside
| Outperform |
7 Dec ‘22
2 years ago |
|
|
9
Genmab
GMAB
$16.9B
| $27.54 | $33 |
20%
upside
| Market Perform |
10 Nov ‘22
2 years ago |
|
|
BCYC
10
Bicycle Therapeutics
BCYC
$496M
| $7.16 | $50 |
598%
upside
| Outperform |
22 Aug ‘22
3 years ago |
|
11
Revolution Medicines
RVMD
$7.57B
| $40.50 | $30 |
26%
downside
| Outperform |
10 Aug ‘22
3 years ago |
|
12
MacroGenics
MGNX
$126M
| $2 | $12 |
500%
upside
| Outperform |
9 Aug ‘22
3 years ago |
|
13
Mersana Therapeutics
MRSN
$34M
| $6.82 | $350 |
5,032%
upside
| Outperform |
9 Aug ‘22
3 years ago |
|
14
Immatics
IMTX
$761M
| $6.26 | $26 |
315%
upside
| Outperform |
3 Jun ‘22
3 years ago |
|
|
15
Zai Lab
ZLAB
$3.42B
| $30.76 | $95 |
209%
upside
| Outperform |
11 May ‘22
3 years ago |
|
|
ADAP
16
Adaptimmune Therapeutics
ADAP
$10.9M
| $0.0410 | $3 |
7,217%
upside
| Market Perform |
9 May ‘22
3 years ago |
|
17
Kura Oncology
KURA
$713M
| $8.22 | $28 |
241%
upside
| Outperform |
25 Feb ‘22
3 years ago |
|
18
Xencor
XNCR
$610M
| $8.55 | $53 |
520%
upside
| Outperform |
5 Aug ‘21
4 years ago |
|